Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
17.55B | 16.75B | 14.24B | 12.68B | 11.89B | 9.91B | Gross Profit |
11.79B | 11.49B | 9.89B | 8.68B | 8.13B | 6.40B | EBIT |
3.08B | 2.60B | 2.34B | 1.65B | 2.04B | 1.04B | EBITDA |
4.09B | 3.94B | 3.45B | 2.74B | 2.52B | 1.51B | Net Income Common Stockholders |
2.03B | 1.85B | 1.59B | 698.00M | 1.04B | -140.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
570.00M | 414.00M | 865.00M | 928.00M | 1.93B | 1.73B | Total Assets |
32.89B | 39.40B | 35.14B | 32.47B | 32.23B | 30.78B | Total Debt |
9.37B | 11.15B | 9.49B | 9.28B | 9.45B | 9.54B | Net Debt |
8.79B | 10.73B | 8.63B | 8.35B | 7.53B | 7.80B | Total Liabilities |
14.78B | 17.39B | 15.61B | 14.90B | 15.61B | 15.45B | Stockholders Equity |
17.85B | 21.77B | 19.28B | 17.57B | 16.62B | 15.33B |
Cash Flow | Free Cash Flow | ||||
2.87B | 2.65B | 1.70B | 914.00M | 1.32B | 1.13B | Operating Cash Flow |
3.81B | 3.44B | 2.50B | 1.53B | 1.87B | 1.51B | Investing Cash Flow |
-5.90B | -5.69B | -2.57B | -2.01B | -1.60B | -411.00M | Financing Cash Flow |
2.15B | 1.81B | 5.00M | -548.00M | -95.00M | 293.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $33.98B | 64.32 | 23.72% | ― | 9.11% | -17.87% | |
80 Outperform | $232.41B | 17.33 | 30.66% | 1.71% | 5.00% | 139.98% | |
78 Outperform | $146.71B | 51.81 | 14.26% | 0.85% | 10.76% | -15.22% | |
75 Outperform | $112.15B | 24.22 | 9.49% | 3.20% | 3.62% | 31.18% | |
73 Outperform | $151.04B | 74.80 | 9.65% | ― | 19.35% | 14.31% | |
71 Outperform | $45.47B | 51.02 | 16.73% | ― | -9.84% | -35.77% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% |
On May 28, 2025, Boston Scientific announced the discontinuation of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, ceasing global sales and halting pursuit of FDA approval due to increased regulatory demands. Despite the financial implications, the company expects to meet its sales and earnings guidance for 2025, though it is withholding reaffirmation of its GAAP EPS guidance until further updates in its second quarter earnings call.
The most recent analyst rating on (BSX) stock is a Buy with a $113.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
On May 1, 2025, Boston Scientific held its Annual Meeting of Stockholders virtually, where all 10 director nominees were elected for a one-year term. Additionally, stockholders approved the compensation for the company’s Named Executive Officers, ratified the appointment of Ernst & Young LLP as the independent public accounting firm for 2025, and supported a proposal for a simple majority vote, indicating strong shareholder engagement and support for the company’s governance and strategic direction.
On April 23, 2025, Boston Scientific announced the retirement of Dan Brennan, its Chief Financial Officer, after nearly 30 years with the company. Brennan will be succeeded by Jon Monson, currently the Senior Vice President of Investor Relations, effective June 30, 2025. Monson, with over 25 years at Boston Scientific, brings extensive financial expertise and will oversee several key company functions. This leadership transition is expected to ensure continuity and further strengthen the company’s financial strategies and operations.